Quantcast

Nobles Medical Technologies II Receives US Patent for “Suturing and Method” for its NobleStitch Technology

September 13, 2013

Nobles Medical Technologies II today announced that it has received another US Patent for its NobleStitch Technology.

Fountain Valley, California (PRWEB) September 13, 2013

Nobles Medical Technologies II today announced that it has received another US Patent for its NobleStitch Technology. The patent is for the Device and Method of our suturing technology. This patent shows the broad coverage of our method as used throughout the entire body and all biological tissue.

Prof. Dr. Anthony Nobles, CEO of NMT2 and co-inventor on the issued patent commented, “Intellectual property is one of the most valuable assets we have, in the medical device industry patents represent one of the greatest measurements of the value of the company. This patent carry’s broad coverage for all of our applications for our technology and is a critical piece of our portfolio.”

Ben Brosch, President of NMT2 and co-inventor on the issued patent commented, “We strive to protect our inventions with strong patents that help us protect our technology. We continuously file new patents and have grown an extensive portfolio of patents and trademarks adding value to our company and its shareholders”.

About Patent Foramen Ovale (PFO)

A PFO is a tunnel that exists between the left and right atrium of the heart. The tunnel, which is part of the normal fetal anatomy, should close shortly after birth. In 27% of the population the tunnel never closes. This tunnel can then allow clots and other chemicals to pass from the right to the left side of the heart freely bypassing the filter of the lungs. These clots and chemicals can cause strokes and other conditions such as severe migraines.

About the NobleStitch EL System

Nobles Medical Technologies II's NobleStitch EL is a catheter based system that allows a physician to place a suture in the PFO tunnel in the heart through a percutaneous puncture in the leg, in many cases under a local anesthetic in a catheter lab rather than an operating room. This eliminates the need for open-heart surgery or placement of a large metallic implant in the heart. The NobleStitch is not a “device” or mechanical implant it only places a simple polypropylene suture in the heart. By closing the hole or PFO, the therapy will reduce or eliminate the shunting from the right to the left side of the heart allowing the lungs to filter the clots and other chemicals from making it to the brain, potentially halting strokes and severe migraines and enabling patients to live a higher-quality life.

About Nobles Medical Technologies II

Nobles Medical Technologies II is a global structural heart company devoted to improving life through the development of its products and technologies. Nobles Medical Technologies II is focused on suture based solutions for the septum. The NobleStitch is available in Europe and is undergoing and IRB study for specific indication in the US. The NobleStitch has CE mark for “Cardiovascular suturing and PFO closure” and US FDA 510k clearance for “vascular suturing”

Visit Nobles Medical Technologies II http://www.noblesmedicaltechnology.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/9/prweb11118545.htm


Source: prweb



comments powered by Disqus